LAPOINTE ANTHONY GREGG 4

What Happened
Anthony Gregg Lapointe, a director of Astria Therapeutics (ATXS), had multiple derivative holdings disposed to the issuer on January 23, 2026 as part of the merger with BioCryst. The Form 4 lists five disposition entries totaling 79,749 derivative securities (post 1-for-6 reverse split adjustment). The filing does not report per-share prices or a total cash amount; a merger footnote states that any in‑the‑money options were canceled in exchange for cash equal to (shares × ($13.00 − exercise price)), while out‑of‑the‑money options were canceled for no consideration.

Key Details

• Transaction date: 2026-01-23 (reported on the same date) — filing appears timely.
• Reported disposals: 16,666; 8,333; 14,100; 14,100; and 26,550 derivative securities — total 79,749 (adjusted for a prior 1-for-6 reverse split).
• Price / cash reported on Form 4: N/A (not disclosed). Footnote F2: in‑the‑money options were paid cash per merger formula; out‑of‑the‑money options were canceled for no consideration.
• Transaction code: D (Disposition) of derivative securities (not an open-market sale).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote F1: quantities reflect the 1-for-6 reverse split effective Aug 19, 2021.

Context
This activity reflects merger-related option cancellation and settlement under the BioCryst merger agreement, not a routine open-market sale or purchase. In‑the‑money options were cashed out per the merger terms; out‑of‑the‑money options were canceled (and those cancellations are exempt from Section 16 reporting and thus not reported). Such transactions are driven by deal terms rather than an immediate market signal from the insider.